Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CLNN

Clene Inc

Feb 13 • 02:21PM ET

4.16

+0.05 1.22 %

Healthcare • Biotechnology • USA • NASD

Peers: CYCN IMNM KNSA MTEM NAII PAVM RARE TERN XAIR

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-3.39	Insider Own	23.18%	Shs Outstand	10.22M	Perf Week	-3.03%
Market Cap	49.00M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-15.36%	Shs Float	9.05M	Perf Month	-18.75%
Enterprise Value	62.39M	PEG	-	EPS next Q	-0.55	Inst Own	6.90%	Short Float	9.08%	Perf Quarter	-55.79%
Income	-30.50M	P/S	233.33	EPS this Y	58.98%	Inst Trans	13.93%	Short Ratio	4.81	Perf Half Y	15.56%
Sales	0.21M	P/B	-	EPS next Y	11.46%	ROA	-113.20%	Short Interest	0.82M	Perf YTD	-29.13%
Book/sh	-1.21	P/C	6.19	EPS next 5Y	65.56%	ROE	-1738.36%	52W High	13.50 -69.19%	Perf Year	-8.77%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	-21.43% 21.17%	ROIC	-441.20%	52W Low	2.28 82.45%	Perf 3Y	-85.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-22.08% -	Gross Margin	-637.38%	Volatility	9.05% 9.17%	Perf 5Y	-98.33%
Dividend TTM	-	EV/Sales	297.09	EPS Y/Y TTM	23.37%	Oper. Margin	-11328.50%	ATR (14)	0.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.52	Sales Y/Y TTM	-49.17%	Profit Margin	-14250.47%	RSI (14)	38.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	-1301.31%	SMA20	-8.48%	Beta	0.67	Target Price	31.86
Payout	-	Debt/Eq	-	Sales Q/Q	-82.76%	SMA50	-24.19%	Rel Volume	0.29	Prev Close	4.11
Employees	76	LT Debt/Eq	-	Earnings	Nov 13 BMO	SMA200	-26.12%	Avg Volume	171.04K	Price	4.16
IPO	Aug 27, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-46.50% -76.67%	Trades		Volume	37,088	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Jan-23-26 01:02AM	Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 (MarketBeat)
Jan-16-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-12-26 08:30AM	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting (GlobeNewswire) -19.00%
Jan-09-26 08:30AM	Clene Announces Registered Direct Offering of Over $28 Million (GlobeNewswire) +7.12%
Dec-09-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire) +6.31%
08:00AM	Loading…
Dec-03-25 08:00AM	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 (GlobeNewswire) -22.03%
Dec-02-25 05:39PM	Clene to Provide CNM-Au8 ALS Program Update (GlobeNewswire)
Nov-20-25 08:00AM	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-13-25 09:00AM	Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -22.42%
08:00AM	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -5.35%
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -14.19%
Oct-20-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Oct-15-25 08:30AM	Clene to Participate in a Panel Discussion at the Maxim Growth Summit (GlobeNewswire)
Sep-25-25 08:00AM	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8 Improves Brain Energy Metabolism in Multiple Sclerosis Patients (GlobeNewswire)
08:30AM	Loading…
Sep-04-25 08:30AM	Clene Presents Preclinical Data Supporting CNM-Au8 for the Treatment of Parkinson's Disease (GlobeNewswire) +6.44%
Sep-02-25 08:00AM	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +20.11%
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:38AM	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Aug-13-25 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Clene to Present at the Canaccord 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks) +7.16%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jun-30-25 08:00AM	Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings (GlobeNewswire)
Jun-09-25 09:00AM	Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025 (ACCESSWIRE)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.53%
08:00AM	Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
08:00AM	Loading…
08:00AM	Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
May-05-25 05:45PM	Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-14-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Apr-08-25 08:00AM	Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8 Treatment At the American Academy of Neurology Late-Breaking Science Session (GlobeNewswire) +7.52%
Apr-01-25 08:30AM	Clene to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire) -16.23%
Mar-25-25 08:30AM	Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 (NewMediaWire) -11.73%
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.31%
08:00AM	Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-12-25 08:00AM	Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment (GlobeNewswire)
Mar-06-25 08:30AM	Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire)
Feb-27-25 09:15AM	Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (ACCESSWIRE)
Feb-25-25 08:00AM	Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8 's Impact on NfL Reduction (GlobeNewswire)
Feb-14-25 11:29AM	Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? (Insider Monkey) +5.48%
Jan-13-25 11:18AM	IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS (NewMediaWire)
Dec-30-24 09:20AM	IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) (NewMediaWire)
Dec-19-24 02:44PM	IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments (NewMediaWire)
08:00AM	Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan (GlobeNewswire)
Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-21-24 07:09AM	Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
May-28-24 07:30AM	Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP) (GlobeNewswire)
May-14-24 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-08-24 12:54PM	CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:55AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-01-24 08:30AM	IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Apr-16-24 04:01PM	Evidence for Clene's CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -6.46% +9.55%
Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ugwumba Chidozie	10% Owner	Feb 03 '26	Sale	4.10	5,559	22,792	550,000	Feb 05 10:18 AM
Symbiosis II LLC	Prior board member	Jan 29 '26	Proposed Sale	4.37	60,842	265,731		Feb 03 03:36 PM
Ugwumba Chidozie	10% Owner	Jan 29 '26	Sale	4.32	15,284	66,027	565,045	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 30 '26	Sale	4.13	5,686	23,483	559,359	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Feb 02 '26	Sale	4.04	3,800	15,352	555,559	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 28 '26	Sale	4.91	8,717	42,800	580,329	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 26 '26	Sale	5.02	6,418	32,218	593,185	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 27 '26	Sale	5.08	4,139	21,026	589,046	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 22 '26	Sale	5.32	12,665	67,378	605,159	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 23 '26	Sale	5.27	5,556	29,280	599,603	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 21 '26	Sale	5.05	12,119	61,201	617,824	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 20 '26	Sale	4.80	12,432	59,674	629,943	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 16 '26	Sale	5.13	7,923	40,645	642,375	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 13 '26	Sale	4.89	26,105	127,653	682,482	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 14 '26	Sale	5.12	19,621	100,460	662,861	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 15 '26	Sale	5.10	12,563	64,071	650,298	Jan 16 11:16 AM
MATLIN DAVID J	Director	Jan 13 '26	Buy	6.50	33,333	216,664	477,824	Jan 13 02:48 PM
Ugwumba Chidozie	10% Owner	Jan 12 '26	Sale	5.50	32,705	179,878	708,587	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 09 '26	Sale	6.27	9,075	56,900	741,292	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 08 '26	Sale	6.09	3,195	19,458	750,367	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 05 '26	Sale	5.87	5,869	34,451	760,611	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 07 '26	Sale	6.29	3,938	24,770	753,562	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 06 '26	Sale	6.04	3,111	18,790	757,500	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Dec 31 '25	Sale	5.81	13,095	76,082	770,495	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Jan 02 '26	Sale	5.73	4,015	23,006	766,480	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Dec 29 '25	Sale	5.95	8,096	48,171	787,728	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 30 '25	Sale	6.03	4,138	24,952	783,590	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 23 '25	Sale	6.27	6,831	42,830	800,664	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 26 '25	Sale	6.32	3,350	21,172	795,824	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 24 '25	Sale	6.27	1,490	9,342	799,174	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 19 '25	Sale	6.45	5,582	36,004	387,568	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 22 '25	Sale	6.54	4,367	28,560	383,201	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 04 '25	Sale	6.73	72,748	489,594	521,620	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 03 '25	Sale	7.86	56,577	444,695	594,368	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 05 '25	Sale	5.94	37,235	221,176	484,385	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 08 '25	Sale	5.70	21,463	122,339	462,922	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 09 '25	Sale	5.95	15,031	89,434	447,891	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 11 '25	Sale	6.81	10,907	74,277	427,063	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 15 '25	Sale	6.49	10,580	68,664	408,880	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 10 '25	Sale	6.42	9,921	63,693	437,970	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 12 '25	Sale	6.79	7,603	51,624	419,460	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 16 '25	Sale	6.31	7,030	44,359	401,850	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 18 '25	Sale	6.33	5,816	36,815	393,150	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 17 '25	Sale	6.61	2,884	19,063	398,966	Dec 18 05:08 PM
Symbiosis II LLC	Prior Board Member	Dec 03 '25	Proposed Sale	7.46	506,384	3,775,481		Dec 05 04:14 PM
General Resonance LLC	10% Owner	Aug 21 '25	Sale	5.34	3,401	18,161	704,591	Aug 21 08:44 PM
General Resonance LLC	10% Owner	Jun 04 '25	Sale	4.04	600	2,424	707,992	Jun 04 03:23 PM
General Resonance LLC	10% Owner	Jun 02 '25	Sale	4.12	600	2,473	708,592	Jun 02 02:39 PM
General Resonance LLC	10% Owner	May 30 '25	Sale	2.80	410	1,148	709,192	May 30 02:40 PM
General Resonance LLC	10% Owner	May 29 '25	Sale	2.73	410	1,119	709,602	May 29 03:58 PM
General Resonance LLC	10% Owner	May 28 '25	Sale	2.60	420	1,090	710,012	May 28 02:05 PM
General Resonance LLC	10% Owner	May 27 '25	Sale	2.45	420	1,029	710,432	May 27 03:29 PM
General Resonance LLC	10% Owner	Mar 19 '25	Sale	4.40	1,400	6,160	710,852	Mar 19 06:47 PM
General Resonance LLC	10% Owner	Mar 18 '25	Sale	4.45	1,333	5,932	712,252	Mar 19 06:47 PM

Open in Screener

PHGE

BiomX Inc

Feb 13 • 02:21PM ET

6.06

-0.34 -5.31 %

Healthcare • Biotechnology • USA • AMEX

Peers: CRSP EDIT NTLA BEAM ADPT SGMO FDMT BLUE SPRO PSTX

Index	-	P/E	-	EPS (ttm)	-30.68	Insider Own	30.47%	Shs Outstand	1.41M	Perf Week	54.20%
Market Cap	9.66M	Forward P/E	-	EPS next Y	-12.23	Insider Trans	0.00%	Shs Float	1.06M	Perf Month	129.55%
Enterprise Value	26.95M	PEG	-	EPS next Q	-5.06	Inst Own	19.76%	Short Float	25.54%	Perf Quarter	-15.24%
Income	-37.38M	P/S	-	EPS this Y	68.12%	Inst Trans	-7.13%	Short Ratio	0.27	Perf Half Y	-36.60%
Sales	0.00M	P/B	-	EPS next Y	39.88%	ROA	-86.77%	Short Interest	0.27M	Perf YTD	224.06%
Book/sh	-5.76	P/C	1.22	EPS next 5Y	41.20%	ROE	-154.50%	52W High	22.06 -72.53%	Perf Year	-64.11%
Cash/sh	4.96	P/FCF	-	EPS past 3/5Y	52.69% 47.40%	ROIC	-236.96%	52W Low	1.50 303.89%	Perf 3Y	-90.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	33.76% 25.16%	Perf 5Y	-99.54%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	54.25%	Oper. Margin	-	ATR (14)	1.07	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.70	EPS Q/Q	-194.29%	SMA20	19.59%	Beta	1.62	Target Price	399.00
Payout	-	Debt/Eq	0.63	Sales Q/Q	-	SMA50	73.17%	Rel Volume	0.05	Prev Close	6.40
Employees	57	LT Debt/Eq	0.50	Earnings	Nov 12 BMO	SMA200	-21.68%	Avg Volume	1.02M	Price	6.06
IPO	Mar 13, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	1.69% -	Trades		Volume	36,824	Change	-5.31%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-21	Initiated	Ladenburg Thalmann	Buy	$25

Jan-27-26 01:41PM	BiomX Issues Statement Regarding Recent Common Stock Trading Activity (GlobeNewswire) +69.51%
01:18PM	BiomX (PHGE) Stock Surges: A Single Buyer Now Owns Nearly 20% (Benzinga)
Dec-30-25 08:15AM	BiomX announces $3M private placement (TipRanks) -7.00%
Dec-29-25 12:00PM	All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy (Zacks)
08:00AM	BiomX Announces $3.0 Million Private Placement (GlobeNewswire)
07:30AM	Loading…
Dec-08-25 07:30AM	BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review (GlobeNewswire) -36.94%
Nov-25-25 04:40PM	BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis (GlobeNewswire) +5.37% -18.69%
Nov-14-25 04:31PM	BiomX Inc. Announces 1-for-19 Reverse Stock Split (GlobeNewswire) +7.46% -15.87%
Nov-12-25 04:02PM	BiomX Inc (PHGE) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -6.99%
07:30AM	BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates (GlobeNewswire)
Nov-05-25 08:30AM	BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025 (GlobeNewswire)
Nov-04-25 08:40AM	BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections (GlobeNewswire) -16.85%
Oct-17-25 08:30AM	BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways (GlobeNewswire)
Sep-04-25 08:30AM	BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-19-25 08:19AM	BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis (GlobeNewswire)
06:30AM	Loading…
Aug-13-25 06:30AM	BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates (GlobeNewswire) -11.69%
Aug-06-25 08:30AM	BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 (GlobeNewswire) +49.43%
Jul-14-25 09:00AM	BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis (GlobeNewswire)
Jul-08-25 08:30AM	BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis (GlobeNewswire)
May-19-25 10:02AM	BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference (GlobeNewswire)
May-16-25 03:13AM	BiomX Inc (PHGE) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
May-15-25 06:30AM	BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates (GlobeNewswire)
May-08-25 07:00AM	BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 (GlobeNewswire)
Apr-18-25 09:55AM	BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-01-25 06:30AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) -11.28%
Mar-31-25 06:30AM	BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) (GlobeNewswire)
Mar-25-25 06:30AM	BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -7.17%
Mar-19-25 12:35PM	BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Feb-26-25 08:00AM	BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million (GlobeNewswire) -14.03%
Dec-16-24 08:00AM	BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards (GlobeNewswire)
06:30AM	Loading…
Nov-14-24 06:30AM	BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire)
Nov-12-24 12:20PM	BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024 (GlobeNewswire)
Oct-16-24 07:05AM	BiomX announces mandatory unit separation (TipRanks)
Oct-15-24 07:00AM	BiomX Announces a Mandatory Unit Separation (GlobeNewswire)
Sep-18-24 08:00AM	BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-04-24 08:00AM	BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 08:00AM	BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 (GlobeNewswire) -7.38%
Aug-16-24 10:55AM	UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-15-24 06:30AM	BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) -11.58%
06:30AM	BiomX Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Aug-08-24 07:00AM	BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024 (GlobeNewswire)
Jul-29-24 07:00AM	BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance (GlobeNewswire) -5.27%
Jul-10-24 06:30AM	BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock (GlobeNewswire) +8.20%
May-30-24 04:50PM	BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) +19.43%
07:00AM	BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024 (GlobeNewswire)
May-21-24 06:30AM	BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates (GlobeNewswire) +6.85%
May-15-24 07:00AM	BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024 (GlobeNewswire)
May-06-24 07:00AM	BiomX to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +6.28%
Apr-23-24 08:00AM	BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) (GlobeNewswire) +17.42%
Apr-18-24 08:00AM	BiomX Announces the Appointment of Susan Blum to its Board of Directors (GlobeNewswire) +5.61%
Apr-05-24 09:55AM	Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-04-24 07:49AM	BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure (GlobeNewswire) +8.57%
Apr-03-24 06:30AM	BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.90%
Mar-27-24 06:30AM	BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024 (GlobeNewswire) +6.07%
Mar-19-24 05:00AM	Telum Therapeutics appoints Dr. Subhendu Basu as CEO (PR Newswire)
Mar-18-24 06:30AM	BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire)
Mar-06-24 07:30AM	BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing (GlobeNewswire) +197.66%
Jan-04-24 08:00AM	BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-30-23 04:15PM	BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023 (GlobeNewswire) -13.67%
Nov-29-23 06:30AM	BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire) -46.43%
Nov-14-23 06:30AM	BiomX Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 08:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-18-23 08:00AM	BiomX Announces the Appointment of Edward L. Williams to its Board of Directors (GlobeNewswire)
Oct-04-23 06:34AM	BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Sep-07-23 09:00AM	BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023 (GlobeNewswire)
Sep-06-23 04:05PM	BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 06:30AM	BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -9.29%
Aug-02-23 04:30PM	BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023 (GlobeNewswire)
Jun-08-23 05:00PM	NYSE American Initiates Delisting Proceedings for BiomX Warrants (GlobeNewswire)
May-31-23 03:00AM	BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC) (GlobeNewswire) +13.56%
May-15-23 06:30AM	BiomX Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.17%
May-12-23 08:00AM	BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors (GlobeNewswire) +9.97%
May-08-23 06:30AM	BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023 (GlobeNewswire)
May-05-23 06:30AM	BiomX Announces Second Closing of $7.5 Million Private Placement (GlobeNewswire) +7.18%
Mar-29-23 06:30AM	BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-23 07:00AM	BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023 (GlobeNewswire) +7.00%
Feb-22-23 06:35AM	BiomX Announces $7.5 Million Private Placement (GlobeNewswire)
06:30AM	BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis (GlobeNewswire)
Nov-29-22 09:10AM	BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage (GlobeNewswire) +6.50%
Nov-09-22 06:30AM	BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-22 09:00AM	BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022 (GlobeNewswire)
Sep-11-22 07:22AM	BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference (Business Wire)
Aug-10-22 06:30AM	BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.41%
Aug-07-22 03:17AM	BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022 (Business Wire)
Aug-04-22 11:20AM	BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease (Business Wire) +6.18%
Jul-06-22 01:45AM	BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange (Business Wire) -5.37%
Jun-28-22 06:30AM	Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers (Business Wire)
Jun-27-22 06:30AM	BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis (Business Wire)
May-24-22 01:52AM	BiomX Announces Corporate Restructuring (Business Wire) +8.74%
May-20-22 08:00AM	BiomX Announces Publication in the Journal, Bioinformatics (Business Wire)
May-11-22 06:30AM	BiomX Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire) -6.09%
May-06-22 07:00AM	BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients (Business Wire)
May-05-22 08:00AM	BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022 (Business Wire)
Mar-30-22 06:30AM	BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (Business Wire) +14.38%
Mar-23-22 08:00AM	BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022 (Business Wire)
Feb-24-22 08:00AM	BiomX Presenting at Three Upcoming Investor Conferences (Business Wire)
Jan-04-22 07:00AM	BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation (Business Wire)
Nov-17-21 08:00AM	BiomX Presenting at Two Upcoming Conferences in November (GlobeNewswire)
Nov-15-21 06:00AM	BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:00AM	BiomX to Host Third Quarter 2021 Financial Results Conference Call and Webcast on November 15, 2021 (GlobeNewswire)

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flynn James E	Director	Feb 27 '25	Option Exercise	0.93	706,498	657,467	1,247,054	Mar 03 07:02 PM

CLNN

Clene Inc

PHGE

BiomX Inc

Upgrade your FINVIZ experience